that's the global market that Oppenheimer sees for NeuVax, and without any competition. This means if NeuVax is successful, GALE WILL become the next PCYC. There's all the upside in the world with very little downside. Since there is no competition the FDA has no comparable treatment, and will be more open if data shows any benefit whatsoever.
Adam F would probably kill himself if you're right. He lets his initial opinion blind him so much from realizing when data changes. Adam F operates with a certain mentality: Market cap of company equals clinical success or failure and the price paid to acquire a product (in this case). These have been his two key problems with GALE. Absolutely ignorant